First FDA-approved CAR T Cell Therapy for Lymphoma to Be Available at City of Hope

October 18, 2017 | City of Hope

City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. FDA announced today is the first approved CAR T therapy for adult patients for some types of non-Hodgkin lymphoma

Continue Reading

Honoring CAR T Patient and Pioneer Richard Grady

September 30, 2017 | Behnam Badie, M.D., F.A.C.S.

My life is devoted to finding a cure for brain cancer. Patients come to us seeking miracles, but often what they give us back is invaluable knowledge. Throughout history, patients have helped revolutionize science and medicine. Many patients, like my dad, do not survive. But they leave behind a legacy of knowledge and hope for other patients today, and for future generations. Richard Grady was that kind of patient.

Linda Malkas: Henrietta Lacks Made My Work Possible

June 30, 2017 | Linda Malkas, Ph.D.

Henrietta Lacks certainly influenced my research, and continues to do so. Her impact is great here at City of Hope, as it is around the world. I’m just one scientist whose work has been made possible by Henrietta. There are many of us who owe her a profound debt of gratitude. Internationally, the number of people who have benefited from what she left behind is impossible to calculate.

Molecular profiling unlocks tumor answers

October 27, 2016 | Sumanta K. Pal, M.D.

Molecular profiling, unlike any other type of controversial profiling in the news, is an extremely hot topic in cancer medicine today, and it’s going to have a huge impact on patients, physicians and payers.

Treatment for acute lymphoblastic leukemia patients has improved, but challenges persist

September 14, 2016 | Leti Marquez

Children with acute lymphoblastic leukemia (ALL) are going into remission at higher rates than ever before – thanks to better treatment that stems from leading-edge clinical trials – but adults with ALL still face significant hurdles in overcoming the disease.